// App-Quantinova.ai

TPS5097 : A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).

Researchers

Presenter

  • Neal D. Shore

Principal Investigators

  • Srinivas Vourganti

  • Jonathan L. Silberstein

  • Bruce A. Brown

  • Samuel Wilson

  • Courtney M.P. Hollowell

  • Matthew Cooperberg

  • Gwendoline Shang

  • Neil Eric Fleshner

Medical Centers

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Department of Urology, Rush University Medical Center, Chicago, IL

  • Departments of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA

  • Astellas Pharma, Inc., Northbrook, IL

  • Cook County Health and Hospital System, Chicago, IL

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Medication, Inc., San Francisco, CA

  • Biostatistics, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • Astellas Pharma Inc.

  • Medication, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT02799745

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved